Focus on Focal Therapy for Prostate Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 817

Special Issue Editors


E-Mail Website
Guest Editor
Section of Urology, Department of Surgery, The University of Chicago Medicine & Biological Sciences, Chicago, IL, USA
Interests: prostate cancer; prostate imaging; image-guided and focal treatments for prostate cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Section of Urology, Department of Surgery, The University of Chicago Medicine & Biological Sciences, Chicago, IL, USA
Interests: prostate cancer; prostate imaging; focal therapy

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to the Special Issue in Cancers, titled “Focus on Focal Therapy for Prostate Cancer”. Prostate cancer remains one of the most common malignancies diagnosed worldwide, with substantial treatment challenges. Traditionally, whole-gland therapies such as radical prostatectomy and radiation therapy have demonstrated strong efficacy in controlling the disease. However, these approaches are often accompanied by significant side effects, particularly impacting urinary and sexual function. With advancements in prostate imaging and growing evidence suggesting prognosis is related to the index lesion in prostate cancer, more patients are turning to focal therapy, which targets the lesion instead of the entire gland. Focal therapy has emerged as a promising alternative, potentially minimizing side effects and improving the quality of life for carefully selected patients.

This Special Issue aims to explore the latest advancements in focal therapy treatment. We invite submissions that discuss innovations in the field, such as new techniques, patient selection, functional outcomes, surveillance, and long-term efficacy. This Special Issue will highlight the potential of focal therapy to bridge the gap between active surveillance and radical treatments, offering an individualized approach to prostate cancer care.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Advancements in focal therapy techniques;
  • Imaging technologies;
  • Oncological and functional outcomes;
  • Surveillance following focal therapy treatment;
  • Comparative studies of focal therapy vs. whole-gland therapies.

We look forward to receiving your contributions.

Dr. Abhinav Sidana
Dr. Samuel Tremblay
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • focal therapy
  • prostate cancer treatment
  • image-guided therapy
  • oncological outcomes
  • functional outcome
  • patient selection
  • surveillance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

12 pages, 232 KiB  
Review
Surveillance After Focal Therapy for Prostate Cancer: A Comprehensive Review
by Jason Koehler, Simon Han, Samuel Tremblay, Wei-Wen Hsu, Bora Kalaycioglu, Aytekin Oto and Abhinav Sidana
Cancers 2025, 17(8), 1337; https://doi.org/10.3390/cancers17081337 - 16 Apr 2025
Viewed by 637
Abstract
Focal Therapy (FT) is an emerging treatment modality for prostate cancer (PCa). Due to its novelty, the research exploring how patients should be followed-up after treatment is limited. There is currently no established role for non-prostate-specific-antigen (PSA) biomarkers and PSMA PET. However, a [...] Read more.
Focal Therapy (FT) is an emerging treatment modality for prostate cancer (PCa). Due to its novelty, the research exploring how patients should be followed-up after treatment is limited. There is currently no established role for non-prostate-specific-antigen (PSA) biomarkers and PSMA PET. However, a combination of PSA testing, multiparametric magnetic resonance imaging (mpMRI), and systematic and targeted biopsies should routinely be used for surveillance after FT. PSA values that rise 1.0 ng/mL over the nadir after twelve months or rise 1.5 ng/mL over nadir after twenty-four to thirty-six months should raise suspicion for recurrence. The standard imaging technique is mpMRI, but it can often be difficult to interpret after FT, so using a scoring system such as prostate imaging after focal ablation (PI-FAB) or the transatlantic recommendations for prostate gland evaluation with magnetic resonance imaging after focal therapy (TARGET) allows for greater consistency between readers. This review seeks to summarize the current literature regarding surveillance after FT as it relates to biomarkers, imaging, biopsies, and consensus statements. Full article
(This article belongs to the Special Issue Focus on Focal Therapy for Prostate Cancer)
Back to TopTop